Clinical trial
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma…
NCT00073983 · Sarcoma Alliance for Research through Collaboration, Other · Completed
Key facts
| NCT number | NCT00073983 |
|---|---|
| Title | Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma |
| Official title | Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewing's Sarcoma, Osteosarcoma, Or Unresectable Or Locally Recurrent Chondrosarcoma [SARC Study] |
| Lead sponsor | Sarcoma Alliance for Research through Collaboration, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Drug, Genetic, Other |
| Interventions | filgrastim, pegfilgrastim, docetaxel, gemcitabine hydrochloride, microarray analysis, laboratory biomarker analysis, pharmacokinetic study |
| Enrollment | 54 |
| Start date | Oct 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Dec 11, 2003 |
| Last update posted | Mar 12, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: